Dr. Linda Van Le
Claim this profileUNC Lineberger Comprehensive Cancer Center
Studies Ovarian Tumors
Studies Ovarian Cancer
15 reported clinical trials
42 drugs studied
Area of expertise
1Ovarian Tumors
Stage III
Stage II
Stage IV
2Ovarian Cancer
Stage III
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Linda Van Le is currently running
Ipatasertib + Megestrol Acetate
for Endometrial Cancer
This trial is testing if combining two drugs, ipatasertib and megestrol acetate, is more effective than using megestrol acetate alone for treating women with endometrial cancer that has returned or spread. Ipatasertib blocks enzymes needed for cancer cell growth, while megestrol acetate reduces and blocks estrogen, which some cancer cells need to grow.
Recruiting1 award Phase 1 & 2
CAR-T Cells
for Ovarian Cancer
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. The study team wants to know how much (dose) of the iC9-CAR.B7-H3 T cells are safe to use in patients without causing too many side effects and what is the maximum dose could be tolerated. There are two parts to this study. In part 1, approximately blood will be collected from subjects to prepare the iC9.CAR.B7-H3 T cells. The study team will collect disease-fighting T cells from the blood and modify them to prepare the iC9.CAR.B7-H3 T cells. In part 2, the iC9.CAR.B7-H3 T cells will be given to eligible subjects by infusion three days after completion of lymphodepletion chemotherapy.
Recruiting1 award Phase 1
More about Linda Van Le
Clinical Trial Related1 year of experience running clinical trials · Led 15 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Linda Van Le has experience with
- Paclitaxel
- Carboplatin
- Topotecan
- Pembrolizumab
- External Beam Radiation Therapy
- Olaparib
Breakdown of trials Linda Van Le has run
Ovarian Tumors
Ovarian Cancer
Serous Cystadenocarcinoma
Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Linda Van Le specialize in?
Linda Van Le focuses on Ovarian Tumors and Ovarian Cancer. In particular, much of their work with Ovarian Tumors has involved Stage III patients, or patients who are Stage II.
Is Linda Van Le currently recruiting for clinical trials?
Yes, Linda Van Le is currently recruiting for 6 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Linda Van Le has studied deeply?
Yes, Linda Van Le has studied treatments such as Paclitaxel, Carboplatin, Topotecan.
What is the best way to schedule an appointment with Linda Van Le?
Apply for one of the trials that Linda Van Le is conducting.
What is the office address of Linda Van Le?
The office of Linda Van Le is located at: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the UNC Lineberger Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.